Gnomestar Craft Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Gnomestar Craft has been growing earnings at an average annual rate of 34%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been declining at an average rate of 49.9% per year.
Anahtar bilgiler
34.0%
Kazanç büyüme oranı
37.9%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.1% |
| Gelir büyüme oranı | -49.9% |
| Özkaynak getirisi | n/a |
| Net Marj | -566.3% |
| Son Kazanç Güncellemesi | 31 Dec 2021 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Gnomestar Craft nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -3 | 1 | 0 |
| 30 Sep 19 | 0 | -4 | 2 | 0 |
| 30 Jun 19 | 0 | -4 | 2 | 0 |
| 31 Mar 19 | 0 | -4 | 2 | 0 |
| 31 Dec 18 | 0 | -3 | 2 | 0 |
| 30 Sep 18 | 0 | -3 | 2 | 0 |
| 30 Jun 18 | 0 | -3 | 2 | 0 |
| 31 Mar 18 | 0 | -4 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 3 | 0 |
| 30 Sep 17 | 0 | -8 | 4 | 0 |
| 30 Jun 17 | 0 | -7 | 4 | 0 |
| 31 Mar 17 | 0 | -6 | 3 | 0 |
| 31 Dec 16 | 0 | -6 | 3 | 0 |
| 30 Sep 16 | 0 | -2 | 1 | 0 |
| 30 Jun 16 | 0 | -3 | 2 | 0 |
| 31 Mar 16 | 0 | -2 | 2 | 0 |
Kaliteli Kazançlar: GNOM is currently unprofitable.
Büyüyen Kar Marjı: GNOM is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if GNOM's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare GNOM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: GNOM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Özkaynak Getirisi
Yüksek ROE: GNOM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.